SOLO PARA USO EN INVESTIGACIÓN. Datos de referencia para investigación de laboratorio. No es consejo médico; no apto para consumo humano.
Peptijournal

Comparar compuestos

Seleccione hasta 3 compuestos para comparar protocolos, mecanismos, criterios de valoración y hallazgos de seguridad en paralelo.

PopularesRetatrutide vs TirzepatideSemaglutide vs TirzepatideSemaglutide vs RetatrutideBPC-157 vs TB-500BPC-157 vs GHK-CuSermorelin vs Tesamorelin
NAD+
Mismo objetivo
Incluir al imprimir

Solo afecta la página impresa o el PDF. El aviso de uso exclusivo en investigación siempre se imprime.

Protocolo01
NAD+

Longevidad

Viales · 500 / 1000 mg

01Protocol

Viales
500 / 1000 mg
Datos de dosis
Referencia de laboratorio; no indicado

02Quick calculator

Extraer (100u)

—

Concentración

—

mg/mL

03Mechanism of action

NAD+ is a coenzyme central to energy metabolism and a substrate for sirtuins and PARP enzymes. Most human trials raise NAD+ indirectly with precursors such as nicotinamide riboside (NR); trials of injected NAD+ itself are scarce.

04Study endpoints

  • NADPARK (30 people with early Parkinson's, 30 days) tested oral NR, not NAD+ vials. Brain NAD increases were variable; altered cerebral metabolism and mild clinical improvement were reported in NR recipients whose brain NAD increased. Inflammatory cytokines also decreased.
  • Pilot RCT in 20 older adults with mild cognitive impairment (10 weeks): blood NAD+ rose 2.6-fold with NR; cognition scores stayed stable.

05Safety & regulatory findings

  • Precursors such as NR are sold as dietary supplements; injectable NAD+ is not an FDA-approved drug.
  • Both trials reported NR as well tolerated, with no between-group difference in adverse events in the cognitive-impairment trial. These findings are for NR, not injected NAD+.

06Citations

2 referencias · ver